Biology of the Testis (BITE), Department of Reproduction, Genetics and Regenerative Medicine (RGRG), Vrije Universiteit Brussel (VUB), Brussels, Belgium.
Front Endocrinol (Lausanne). 2022 Mar 10;13:854186. doi: 10.3389/fendo.2022.854186. eCollection 2022.
Due to the growing number of young patients at risk of germ cell loss, there is a need to preserve spermatogonial stem cells for patients who are not able to bank spermatozoa. Worldwide, more and more clinics are implementing testicular tissue (TT) banking programs, making it a novel, yet indispensable, discipline in the field of fertility preservation. Previously, TT cryopreservation was predominantly offered to young cancer patients before starting gonadotoxic chemo- or radiotherapy. Nowadays, most centers also bank TT from patients with non-malignant conditions who need gonadotoxic conditioning therapy prior to hematopoietic stem cell (HSCT) or bone marrow transplantation (BMT). Additionally, some centers include patients who suffer from genetic or developmental disorders associated with prepubertal germ cell loss or patients who already had a previous round of chemo- or radiotherapy. It is important to note that the surgical removal of TT is an invasive procedure. Moreover, TT cryopreservation is still considered experimental as restoration methods are not yet clinically available. For this reason, TT banking should preferably only be offered to patients who are at significant risk of becoming infertile. In our view, TT cryopreservation is recommended for young cancer patients in need of high-risk chemo- and/or radiotherapy, regardless of previous low-risk treatment. Likewise, TT banking is advised for patients with non-malignant disorders such as sickle cell disease, beta-thalassemia, and bone marrow failure, who need high-risk conditioning therapy before HSCT/BMT. TT retrieval during orchidopexy is also proposed for patients with bilateral cryptorchidism. Since patients with a medium- to low-risk treatment generally maintain their fertility, TT banking is not advised for this group. Also for Klinefelter patients, TT banking is not recommended as it does not give better outcomes than a testicular sperm extraction later in life.
由于越来越多的年轻患者有发生生殖细胞丢失的风险,因此需要为无法储存精子的患者保存精原干细胞。目前,全世界越来越多的诊所正在开展睾丸组织(TT)银行项目,这使其成为生育力保护领域中一个新颖但不可或缺的学科。以前,TT 冷冻保存主要提供给在接受性腺毒性化疗或放疗之前的年轻癌症患者。如今,大多数中心也从需要进行性腺毒性预处理的非恶性疾病患者中储存 TT,这些患者需要进行造血干细胞(HSCT)或骨髓移植(BMT)。此外,一些中心还包括患有与青春期前生殖细胞丢失相关的遗传或发育障碍的患者,或已经接受过一轮化疗或放疗的患者。需要注意的是,TT 的切除是一种有创性的手术。此外,由于恢复方法尚未在临床上应用,因此 TT 冷冻保存仍被认为是实验性的。出于这个原因,TT 银行应该只提供给有很大可能不孕的患者。我们认为,无论以前的治疗风险如何,对于需要进行高风险化疗和/或放疗的年轻癌症患者,都推荐进行 TT 冷冻保存。同样,对于镰状细胞病、β-地中海贫血和骨髓衰竭等非恶性疾病患者,在进行 HSCT/BMT 之前需要进行高风险预处理,也建议进行 TT 银行。对于双侧隐睾的患者,也建议在进行隐睾固定术期间取出 TT。由于中低风险治疗的患者通常可以维持生育能力,因此不建议对他们进行 TT 银行。此外,对于 Klinefelter 患者,也不建议进行 TT 银行,因为其效果不如以后进行睾丸精子提取。